Skip to main content

Advertisement

Table 1 Demographic characteristics

From: FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease

AC-AD-002 demography n = 26
Age (years), mean (SD) 67.1 (8.1)
Education level (years), mean (SD) 12.0 (3.7)
Sex
 Male 16 (62%)
 Female 10 (38%)
Ethnic origin
 Caucasian 26 (100%)
MMSE score (before treatment start), mean (SD) 20.7 (4.1)
Modified Hachinski score (before treatment start), mean (SD) 1.0 (0.9)
GDS (before treatment start), mean (SD) 1.3 (1.3)
ApoE status
 Carrier 16 (62%)
 Non-carrier 10 (38%)
Smoking habit
 Smoker 1 (3.8%)
 Non-smoker 25 (96.2%)
Medication status
 Receiving standard AD medication 24 (92.3%)
 Not receiving standard AD medication 2 (7.7%)
  1. Abbreviations: AD Alzheimer’s disease, GDS Geriatric Depression Scale, MMSE Mini Mental State Examination
  2. Data are mean (SD) or number (%). Values labelled as “before treatment start” were recorded at the start of the preceding study and not re-recorded at this study’s screening